Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Eur J Clin Invest. 2012 Mar;42(3):310-20. doi: 10.1111/j.1365-2362.2011.02585.x. Epub 2011 Aug 31.
Topoisomerase IIα (topo IIα) protein expression has prognostic significance in many cancers. However, it is still unclear whether topo IIα protein expression and gene alterations play roles as prognostic factors in diffuse large B-cell lymphoma (DLBCL).
We selected 102 patients with DLBCL who were homogeneously treated with CHOP chemotherapy and followed up. Using tissue microarray technology, all of the cases, consisting of 25 germinal centre B-cell-like (GCB) and 77 nongerminal centre B-cell-like (non-GCB) types, were studied. Topo IIα protein expression was detected by immunohistochemistry. Gene copy number of topo IIα was analysed by chromogenic in situ hybridization. Cox regression, chi-square test and Kaplan-Meier statistics were performed using SPSS 15·0.
Topo IIα protein overexpression was found in 91 (91/102, 89·2%) cases, while topo IIα gene amplification was absent in all cases. Chromosome 17 deletion was identified in 3 (3/102, 2·9%) cases, diploid in 66 (66/102, 64·7%) cases and aneuploidy in 33 (33/102, 32·4%) cases. By multivariate analysis, no significant differences in progression-free survival (PFS) and overall survival (OS) were observed in patients with topo IIα protein overexpression (P > 0·05), while chromosome 17 aneuploidy predicted worse PFS and OS (P < 0·001).
These results suggested that chromosome 17 aneuploidy, but not topo IIα protein expression, could predict worse survival in patients with DLBCL.
拓扑异构酶 IIα（topo IIα）蛋白表达在许多癌症中具有预后意义。然而，topo IIα 蛋白表达和基因改变是否作为弥漫性大 B 细胞淋巴瘤（DLBCL）的预后因素尚不清楚。
我们选择了 102 例接受 CHOP 化疗并进行随访的 DLBCL 患者。使用组织微阵列技术，对所有病例（包括 25 例生发中心 B 细胞样（GCB）和 77 例非生发中心 B 细胞样（non-GCB））进行了研究。采用免疫组织化学法检测 topo IIα 蛋白表达。采用显色原位杂交法分析 topo IIα 基因拷贝数。采用 SPSS 15.0 进行 Cox 回归、卡方检验和 Kaplan-Meier 统计分析。
91 例（91/102，89.2%）病例存在 topo IIα 蛋白过表达，所有病例均不存在 topo IIα 基因扩增。3 例（3/102，2.9%）存在 17 号染色体缺失，66 例（66/102，64.7%）为二倍体，33 例（33/102，32.4%）为非整倍体。多因素分析显示，topo IIα 蛋白过表达的患者无进展生存期（PFS）和总生存期（OS）无显著差异（P > 0.05），而 17 号染色体非整倍体预测 PFS 和 OS 更差（P < 0.001）。
这些结果表明，17 号染色体非整倍体而非 topo IIα 蛋白表达可预测 DLBCL 患者的生存更差。
